| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| review article | Q7318358 |
| P50 | author | Robert W. Buchanan | Q109937282 |
| Brian Kirkpatrick | Q62574216 | ||
| P2093 | author name string | Alex S Cohen | |
| James M Gold | |||
| Alice M Saperstein | |||
| William T Carpenter | |||
| P2860 | cites work | Historical, psychopathological, neurological, and neuropsychological aspects of deficit schizophrenia: a multicenter study | Q28202039 |
| Perceptual asymmetries in schizophrenia: subtype differences in left hemisphere dominance for dichotic fused words | Q34088917 | ||
| A separate disease within the syndrome of schizophrenia | Q34140437 | ||
| Odor identification, eye tracking and deficit syndrome schizophrenia. | Q34312448 | ||
| Memory and executive function impairments in deficit syndrome schizophrenia | Q38440149 | ||
| Information-processing abnormalities as neuropsychological vulnerability indicators for schizophrenia. | Q40605886 | ||
| Recognition of posed and genuine facial expressions of emotion in paranoid and nonparanoid schizophrenia | Q40744749 | ||
| Limbic System Abnormalities Identified in Schizophrenia Using Positron Emission Tomography With Fluorodeoxyglucose and Neocortical Alterations With Deficit Syndrome | Q41127141 | ||
| SPECT imaging, clinical features, and cognition before and after low doses of amisulpride in schizophrenic patients with the deficit syndrome | Q44092149 | ||
| Cognitive patterns in subtypes of schizophrenia | Q46057637 | ||
| Neurocognitive, social, and emotional dysfunction in deficit syndrome schizophrenia | Q46095062 | ||
| Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia | Q48186308 | ||
| Visual perception of line direction in patients with unilateral brain disease | Q48436468 | ||
| Olfaction and social drive in schizophrenia | Q48592074 | ||
| Abnormal patterns of regional cerebral blood flow in schizophrenia with primary negative symptoms during an effortful auditory recognition task | Q48722393 | ||
| The Schedule for the Deficit syndrome: an instrument for research in schizophrenia | Q48914414 | ||
| Clinical correlates of the deficit syndrome of schizophrenia | Q49075231 | ||
| Visual scanpaths to threat-related faces in deluded schizophrenia. | Q51020101 | ||
| Cognitive impairment and enduring negative symptoms: a comparative study of geriatric and nongeriatric schizophrenia patients. | Q51073090 | ||
| Affect recognition in deficit syndrome schizophrenia. | Q51098373 | ||
| Psychopathology and neuropsychological impairments in deficit and nondeficit schizophrenia of Chinese origin. | Q51894320 | ||
| Deficit versus negative syndrome in schizophrenia: prediction of attentional impairment. | Q51929066 | ||
| A brief smell identification test discriminates between deficit and non-deficit schizophrenia. | Q51946448 | ||
| Reexamination of the characteristics of the deficit schizophrenia patients | Q51946654 | ||
| Functional imaging of memory retrieval in deficit vs nondeficit schizophrenia. | Q51979486 | ||
| Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. | Q52038454 | ||
| Neuropsychological impairments in deficit vs nondeficit forms of schizophrenia. | Q52056404 | ||
| Deficit and nondeficit forms of schizophrenia: neuropsychological evaluation. | Q52072882 | ||
| [Tolerance of neuroleptics, deficit syndrome and cognitive functions] | Q52201297 | ||
| Closure as affected by viewing time and multiple visual fixations. | Q52363701 | ||
| A rating scale for extrapyramidal side effects | Q53780342 | ||
| Olfactory identification and WAIS-R performance in deficit and nondeficit schizophrenia | Q61242538 | ||
| Attentional impairments in deficit and nondeficit forms of schizophrenia | Q73120148 | ||
| Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates | Q73597908 | ||
| Behavioural dysregulation of decision-making in deficit but not nondeficit schizophrenia patients | Q73801263 | ||
| Cognitive deficit and schizophrenia | Q73829182 | ||
| Trail making and olfaction in schizophrenia: implications for processing speed | Q80020192 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | neuropsychology | Q3872 |
| meta-analysis | Q815382 | ||
| P304 | page(s) | 1201-1212 | |
| P577 | publication date | 2006-12-11 | |
| P1433 | published in | Schizophrenia Bulletin | Q4049133 |
| P1476 | title | Neuropsychology of the deficit syndrome: new data and meta-analysis of findings to date | |
| P478 | volume | 33 |
| Q47701023 | A Randomized Clinical Trial of Oxytocin or Galantamine for the Treatment of Negative Symptoms and Cognitive Impairments in People With Schizophrenia |
| Q35121033 | A comparison of the effectiveness of problem solving training and of cognitive-emotional rehabilitation on neurocognition, social cognition and social functioning in people with schizophrenia |
| Q35738993 | Are Negative Symptoms Dimensional or Categorical? Detection and Validation of Deficit Schizophrenia With Taxometric and Latent Variable Mixture Models |
| Q50622213 | Association between olfactory identification and parkinsonism in patients with non-affective psychosis. |
| Q36332243 | Attacking Heterogeneity in Schizophrenia by Deriving Clinical Subgroups From Widely Available Symptom Data |
| Q38559235 | Avolition, Negative Symptoms, and a Clinical Science Journey and Transition to the Future. |
| Q54364120 | BDNF rs 6265 polymorphism and COMT rs 4680 polymorphism in deficit schizophrenia in Polish sample. |
| Q99732019 | Biotyping in psychosis: using multiple computational approaches with one data set |
| Q89642438 | Cognitive Impairment and Diminished Neural Responses Constitute a Biomarker Signature of Negative Symptoms in Psychosis |
| Q33566114 | Cognitive impairment in schizophrenia and affective psychoses: implications for DSM-V criteria and beyond |
| Q48494944 | Cognitive precursors of severe mental disorders |
| Q48016632 | Convergence and Divergence of Brain Network Dysfunction in Deficit and Non-deficit Schizophrenia |
| Q35818882 | Cortical structural abnormalities in deficit versus nondeficit schizophrenia |
| Q60959871 | DNA Methylation and Gene Expression of Matrix Metalloproteinase 9 Gene in Deficit and Non-deficit Schizophrenia |
| Q37287211 | Deficit schizophrenia: an update |
| Q37151244 | Differences in glucose tolerance between deficit and nondeficit schizophrenia |
| Q35785464 | Differential patterns of premorbid social and academic deterioration in deficit and nondeficit schizophrenia |
| Q34443228 | Distinct episodic verbal memory profiles in schizophrenia |
| Q36471475 | Dysfunctional attitudes and expectancies in deficit syndrome schizophrenia |
| Q50716056 | Executive functioning and psychopathological profile in relatives of individuals with deficit v. non-deficit schizophrenia: a pilot study. |
| Q50998462 | General and domain-specific neurocognitive impairments in deficit and non-deficit schizophrenia. |
| Q36877510 | Gray matter volume alterations in first-episode drug-naïve patients with deficit and nondeficit schizophrenia. |
| Q89022428 | Impaired Prefrontal Cortical Dopamine Release in Schizophrenia During a Cognitive Task: A [11C]FLB 457 Positron Emission Tomography Study |
| Q34393630 | Impaired insight in patients with newly diagnosed nonaffective psychotic disorders with and without deficit features |
| Q34703195 | Investigational drugs for schizophrenia targeting the dopamine receptor: phase II trials |
| Q43513717 | Is executive impairment associated with schizophrenic syndromes? A meta-analysis |
| Q37612534 | Is late-onset schizophrenia a subtype of schizophrenia? |
| Q39233330 | Managing Negative Symptoms of Schizophrenia: How Far Have We Come? |
| Q47898982 | Mapping Convergent and Divergent Cortical Thinning Patterns in Patients With Deficit and Nondeficit Schizophrenia. |
| Q30913824 | Neurobiological background of negative symptoms |
| Q37975551 | Neurocognition and neuroimaging of persistent negative symptoms of schizophrenia |
| Q48289102 | Neurocognition in psychometrically defined college Schizotypy samples: we are not measuring the "right stuff". |
| Q35779544 | Neurocognitive Impairments in Deficit and Non-Deficit Schizophrenia and Their Relationships with Symptom Dimensions and Other Clinical Variables |
| Q39281301 | Neurocognitive impairment in deficit and non-deficit schizophrenia: a meta-analysis. |
| Q48076142 | Neurocognitive impairment in the deficit subtype of schizophrenia |
| Q50645808 | Neurodevelopmental origin of cognitive impairment in schizophrenia. |
| Q41600823 | Neuropsychological Profile of Specific Executive Dysfunctions in Patients with Deficit and Non-deficit Schizophrenia |
| Q34234494 | Neuropsychological functioning and social anhedonia: three-year follow-up data from a longitudinal community high risk study. |
| Q51813550 | Not All Differences between Patients with Schizophrenia and Healthy Subjects Are Pathological: Performance on the Conners' Continuous Performance Test. |
| Q33950864 | Olfactory hedonic judgment in patients with deficit syndrome schizophrenia |
| Q41197010 | Oxidative stress, prefrontal cortex hypomyelination and cognitive symptoms in schizophrenia |
| Q37076288 | Patterns of structural MRI abnormalities in deficit and nondeficit schizophrenia |
| Q34830664 | Posttraumatic stress disorder and negative symptoms of schizophrenia |
| Q35118483 | Predictors of neuropsychological effort test performance in schizophrenia |
| Q38675564 | Primary, Enduring Negative Symptoms: An Update on Research |
| Q37602615 | Progress in the study of negative symptoms |
| Q30439312 | Psychiatric symptom versus neurocognitive correlates of diminished expressivity in schizophrenia and mood disorders |
| Q57833617 | Psychosocial function in schizophrenia and bipolar disorder: Relationship to neurocognition and clinical symptoms |
| Q30397612 | Speech deficits in serious mental illness: a cognitive resource issue? |
| Q35892303 | Study protocol: a randomised controlled trial of cognitive remediation for a national cohort of forensic mental health patients with schizophrenia or schizoaffective disorder. |
| Q34254426 | Testing trait depression as a potential clinical domain in schizophrenia |
| Q35390239 | The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later? |
| Q30487850 | The evolution of drug development in schizophrenia: past issues and future opportunities |
| Q33641039 | The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample |
| Q37794502 | Thinking Glutamatergically: Changing Concepts of Schizophrenia Based Upon Changing Neurochemical Models |
| Q34796205 | Toward defining schizophrenia as a more useful clinical concept |
| Q38647035 | Treatment for Negative Symptoms in Schizophrenia: A Comprehensive Review |
| Q30378034 | Vocal expression in schizophrenia: Less than meets the ear. |
| Q37602624 | William T. Carpenter Jr: 35 years of clinical trials |
Search more.